Skip to main content

Table 4 Distribution of means of variables selected for the final algorithm in test data set using Linear Discriminant Analysis (LDA) model, case study performed in 2019–20 to estimate the incidence of Diabetes Mellitus in France

From: Use of artificial intelligence for public health surveillance: a case study to develop a machine Learning-algorithm to estimate the incidence of diabetes mellitus in France

Ranked ≠

Categories

Variables

Mean (incident diabetes group) n = 2921

Mean (non- diabetes group) n = 6010

P value (Student’s t-test)

1

AGE

Age in years

56.70*

43.69

< 0.0001

2

BIOLOGICAL TESTS

Nb. of reimbursement of Alkaline Phosphatase test in last 2 years

0.36*

0.20

< 0.0001

3

BIOLOGICAL TESTS

Nb. of reimbursement of Gamma Glutamyle Transferase test in last 2 years

1.05*

0.40

< 0.0001

4

BIOLOGICAL TESTS

Nb. of reimbursement of Transaminases (ALAT and ASAT, TGP and TGO) blood test in last 2 years

1.33*

0.63

< 0.0001

5

BIOLOGICAL TESTS

Nb. Of reimbursement of Uric Acid (Uricemia) blood test in last 2 years

0.47*

0.22

< 0.0001

6

BIOLOGICAL TESTS

Nb. of reimbursement of Glucose blood test in last 2 years

1.29*

0.74

< 0.0001

7

BIOLOGICAL TESTS

Nb. Of reimbursement of Creatinine level blood test in last 2 years

1.09*

0.39

< 0.0001

8

BIOLOGICAL TESTS

Nb. of reimbursement of Exploration of a Lipid Anomaly (ELA) blood test in last 2 years

1.20*

0.65

< 0.0001

9

BIOLOGICAL TESTS

Nb. Of reimbursement of HbA1c tests in last 2 years

0.20*

0.04

< 0.0001

10

BIOLOGICAL TESTS

Nb. Of reimbursement of C-Reactive Protein test in last 2 years

1.16*

0.38

< 0.0001

11

DRUGS

Nb. Of reimbursement of Proton pump inhibitors drugs in last 2 years

3.67*

0.54

< 0.0001

12

DRUGS

Nb. Of reimbursement of other antidiarrheal drugs in last 2 years

0.21*

0.03

< 0.0001

13

DRUGS

Nb. of reimbursement of Penicillin with broad spectrum drugs in last 2 years

0.74*

0.23

< 0.0001

14

DRUGS

Nb. Of reimbursement of bacterial and viral vaccines, combined (diphtheria-haemophilus influenza B-pertussis-tetanus-hepatitis B-meningococcal A + C) in last 2 years

0.23*

0.13

< 0.0001

15

DRUGS

Nb. of reimbursement of Acetic acid derivatives and related substances in last 2 years

0.57*

0.19

< 0.0001

16

DRUGS

Nb. of reimbursement of Propionic acid derivatives in last 2 years

1.53*

1.07

< 0.0001

17

DRUGS

Nb. of reimbursement of Anilides (Paracetamol) in last 2 years

3.65*

1.69

< 0.0001

18

MEDICAL ACTS

Nb. of reimbursement of Fundus examination by biomicroscopy with contact lens in last 2 years

0.30*

0.03

< 0.0001

19

MEDICAL ACTS

Nb. of reimbursement of functional examination of the ocular motricity in last 2 years

0.19*

0.08

< 0.0001

20

MEDICAL ACTS

Nb. of reimbursement of binocular vision examination in last 2 years

0.32*

0.10

< 0.0001

21

MEDICAL ACTS

Nb. of reimbursement of mammography in last 2 years

0.12*

0.10

0.0062

22

MEDICAL ACTS

Nb. Of reimbursement of X-ray thorax in the previous 2 years in last 2 years

0.20*

0.07

< 0.0001

23

HOSPITALIZATION

Total number of hospitalizations without a procedure (i.e. dialysis, chemotherapy) in last 2 years

0.89*

0.26

< 0.0001

  1. *Highest mean
Back to article page

Archives of Public Health

ISSN: 2049-3258